Achaogen raises $56M for antibiotic work

2009 Fierce 15 winner Achaogen has announced that it has raised $56 million in a series C round of financing. New investors Frazier Healthcare Ventures and Alta Partners joined a syndicate of previous investors in the round.

When we last checked in with Achaogen, the San Francisco-based developer used chemistry to revive an old generation of antibiotics called aminoglycosides. The result was next-gen approach dubbed neoglycosides, which the company hopes can treat multi-drug resistant bacterial infections. Achaogen's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase I clinical testing and is now headed for Phase II trials. The drug is being explored as a treatment for multi-drug resistant (MDR) Gram-negative bacteria and MRSA.

"Our mission is to discover and develop life-saving antibiotics," states CEO Kevin Judice (photo). "This financing together with non-dilutive capital that we have secured through partnerships with various government agencies will enable us to advance multiple clinical programs, including conducting a Phase II study in complicated urinary tract infections of ACHN-490, our lead candidate for multi-drug resistant bacterial infections."

- see Achaogen's release

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.